

In the Specification:

Replace the Amendment of February 1, 2005 after line **24** of Page **9** as follows:

Fig. 1 is a graph of murine bone marrow stem cell proliferation and Fig. 2 is a graph of NO production in murine macrophage cells;

Figs. 3, 4 and 5 are graphs of Dextran-FITC conjugate take up by human dendritic cells differentiated from monocytes isolated from peripheral blood;

Fig 6 is a graph of CD40 surface marker expression from human dendritic cells;

Figs. 7, 8 and 9 are graphs of CD86, CD83 and CD80 surface marker expression, respectively, from human dendritic cells;

Fig. 10 is a graph of OM-294-MP and OM-294-DP effects of TNF- α production by predendritic cells at DC-6 stage;

Fig. 11 is a graph of OM-294-MP and OM-294-DP on IL12 p70 production by predendritic cells at DC-6 stage;

Fig. 12 is a graph of the effect of OM-294-MP on IL12 p70 production in the supernatant fluid of monocytes;

Figs. 13, 14 and 15 are graphs of ELISA 2, 3 and 4 weeks after the first, second and third immunization of mice with the synthetic peptide Pb CS His6 242-310 amino acid sequence of Plasmodium berghei circumsporozoite;

Fig. 16 is a graph of antibody titer before and after immunization of mice with the synthetic peptide Pb CS His-6 242-310 amino acid sequence of Plasmodium berghei circumsporozoite;

Figs. 17 to 20 are graphs of ELISPOT IFN- γ IFN producing lymphocytes after immunization of mice with the synthetic peptide Pb CS His-6 242-310 amino acid sequence of Plasmodium bergei circumsporozoite;

Fig. 21 is an electropherogram;

Figs. 22 to 29 are graphs of specific mouse antibodies directed to specific antigens;

Figs. 30(a) and 30(b) are graphs of anti-gp63 immune response and Figs. 31(a) and 31(b) are graphs of lymph node lymphocyte response;

Figs. 32(a) and 32(b) are graphs of anti-LmCPb immune response;

Figs. 33 to 38 are schemes outlining the synthetic processes of the invention;

Figs. 39 to 41 are Mass spectra of the compounds of the invention;

Figs. 42 and 43 are ^1H -NMR spectra of the compounds of the invention;

Figs. 44 and 45 are ^{13}C -NMR spectra of the compounds of the invention;

Figs. 46 and 47 are ^{31}P -NMR spectra of the compounds of the invention.